The Food and Drug Administration (FDA) has approved a new medicine called Exdensur (depemokimab) for teens and adults ages 12 and older with severe #asthma. Learn more: https://community.aafa.org/blog/new-biologic-treatment-approved-for-severe-asthma
January 26, 2026 at 8:53 PM
The Food and Drug Administration (FDA) has approved a new medicine called Exdensur (depemokimab) for teens and adults ages 12 and older with severe #asthma. Learn more: https://community.aafa.org/blog/new-biologic-treatment-approved-for-severe-asthma
Life-saving asthma drug taken twice a year slashes hospital admissions — A new asthma drug, depemokimab (brand name Exdensur), developed by GSK, is set to launch in Britain in the first half of 2026, … https://ranked.news/eng/life-saving-asthma-drug-taken-twice-a-year-slashes-hospital-admissions?u=b
December 29, 2025 at 6:03 PM
Life-saving asthma drug taken twice a year slashes hospital admissions — A new asthma drug, depemokimab (brand name Exdensur), developed by GSK, is set to launch in Britain in the first half of 2026, … https://ranked.news/eng/life-saving-asthma-drug-taken-twice-a-year-slashes-hospital-admissions?u=b
Exdensur: ‘Life-changing’ asthma drug only requires two jabs a year
https://www.europesays.com/uk/659922/
Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The…
https://www.europesays.com/uk/659922/
Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The…
Exdensur: ‘Life-changing’ asthma drug only requires two jabs a year - United Kingdom
Your support helps us to tell the story
www.europesays.com
December 29, 2025 at 10:00 AM
Exdensur: ‘Life-changing’ asthma drug only requires two jabs a year
https://www.europesays.com/uk/659922/
Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The…
https://www.europesays.com/uk/659922/
Your support helps us to tell the story From reproductive rights to climate change to Big Tech, The…
Exdensur: ‘Life-changing’ asthma drug only requires two jabs a year | The Independent www.independent.co.uk/news/health/...
‘Life-changing’ asthma drug only requires two jabs a year
A trial cut hospital admissions by 72 per cent
www.independent.co.uk
December 28, 2025 at 5:44 PM
Exdensur: ‘Life-changing’ asthma drug only requires two jabs a year | The Independent www.independent.co.uk/news/health/...
Exdensur: ‘Life-changing’ asthma drug only requires two jabs a year
A trial cut hospital admissions by 72 per cent
© Getty Images/iStockphoto
A trial cut hospital admissions by 72 per cent
© Getty Images/iStockphoto
www.independent.co.uk
December 28, 2025 at 3:29 PM
Exdensur: ‘Life-changing’ asthma drug only requires two jabs a year
A trial cut hospital admissions by 72 per cent
© Getty Images/iStockphoto
A trial cut hospital admissions by 72 per cent
© Getty Images/iStockphoto
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.
https://www.medpagetoday.com/allergyimmunology/asthma/119054
https://www.medpagetoday.com/allergyimmunology/asthma/119054
First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma
Ultra-long-acting depemokimab offers potential for better uptake
www.medpagetoday.com
December 19, 2025 at 10:53 PM
The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced.
https://www.medpagetoday.com/allergyimmunology/asthma/119054
https://www.medpagetoday.com/allergyimmunology/asthma/119054
[Gsk.com]Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma - GSK SWIFT data included reduction in exacerbations requiring hospitalisation and/or emergency department visits with depemokimab.
December 19, 2025 at 11:30 AM
[Gsk.com]Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma - GSK SWIFT data included reduction in exacerbations requiring hospitalisation and/or emergency department visits with depemokimab.
FDA Approves EXDENSUR (depemokimab-ulaa), New Biologic for Severe Asthma
December 18, 2025 at 2:05 PM
FDA Approves EXDENSUR (depemokimab-ulaa), New Biologic for Severe Asthma
Breaking news for #asthma specialists: The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype.
Learn more (via @medpagetoday.com): www.medpagetoday.com/allergyimmun...
Learn more (via @medpagetoday.com): www.medpagetoday.com/allergyimmun...
First Twice-Yearly Biologic Approved for Severe Eosinophilic Asthma
Ultra-long-acting depemokimab offers potential for better uptake
www.medpagetoday.com
December 17, 2025 at 7:30 PM
Breaking news for #asthma specialists: The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype.
Learn more (via @medpagetoday.com): www.medpagetoday.com/allergyimmun...
Learn more (via @medpagetoday.com): www.medpagetoday.com/allergyimmun...
The MHRA has approved depemokimab (Exdensur), the first twice-yearly biological medicine for use as an add-on treatment for asthma in adults and adolescents aged 12 years and older, and as an add-on treatment for severe chronic rhinosinusitis with nasal polyps in adults.
www.gov.uk/government/n...
www.gov.uk/government/n...
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps
As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review.
www.gov.uk
December 17, 2025 at 4:02 PM
The MHRA has approved depemokimab (Exdensur), the first twice-yearly biological medicine for use as an add-on treatment for asthma in adults and adolescents aged 12 years and older, and as an add-on treatment for severe chronic rhinosinusitis with nasal polyps in adults.
www.gov.uk/government/n...
www.gov.uk/government/n...
The U.S. Food and Drug Administration (FDA) has approved GSK’s Exdensur (depemokimab-ulaa) as a new biologic add-on maintenance treatment for people aged 12 and older with severe asthma with an eosinophilic phenotype.
December 17, 2025 at 2:16 PM
The U.S. Food and Drug Administration (FDA) has approved GSK’s Exdensur (depemokimab-ulaa) as a new biologic add-on maintenance treatment for people aged 12 and older with severe asthma with an eosinophilic phenotype.
Regulators in the #UK and #US are the first to approve #GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe #asthma that has been billed as a major new product for the drugmaker.
pharmaphorum.com/news/uk-us-a...
pharmaphorum.com/news/uk-us-a...
December 17, 2025 at 11:31 AM
Regulators in the #UK and #US are the first to approve #GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe #asthma that has been billed as a major new product for the drugmaker.
pharmaphorum.com/news/uk-us-a...
pharmaphorum.com/news/uk-us-a...
GSK's Exdensur approved in US as first twice-yearly asthma treatment firstwordpharma.com/story/6764544
December 17, 2025 at 11:20 AM
GSK's Exdensur approved in US as first twice-yearly asthma treatment firstwordpharma.com/story/6764544
#GSK Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
https://www.stocktitan.net/news/GSK/exdensur-depemokimab-approved-by-us-fda-for-the-treatment-of-severe-alzuzvy4xbi8.html
https://www.stocktitan.net/news/GSK/exdensur-depemokimab-approved-by-us-fda-for-the-treatment-of-severe-alzuzvy4xbi8.html
Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
GSK plc today announced that the US Food and Drug Administration has approved Exdensur as an add-on maintenance treatment of severe asthma characterised by an eosinophilic phenotype in adult and pediatric patients aged 12 years and older. The FDA approval of Exdensur is based on data from the SWIFT-1 and SWIFT-2 phase III trials. In these studies,...
www.stocktitan.net
December 17, 2025 at 2:55 AM
#GSK Exdensur (depemokimab) approved by US FDA for the treatment of severe asthma
https://www.stocktitan.net/news/GSK/exdensur-depemokimab-approved-by-us-fda-for-the-treatment-of-severe-alzuzvy4xbi8.html
https://www.stocktitan.net/news/GSK/exdensur-depemokimab-approved-by-us-fda-for-the-treatment-of-severe-alzuzvy4xbi8.html
GSK: EXDENSUR (DEPEMOKIMAB) APPROVED BY US FDA FOR TREATMENT OF SEVERE ASTHMA
December 16, 2025 at 11:10 PM
GSK: EXDENSUR (DEPEMOKIMAB) APPROVED BY US FDA FOR TREATMENT OF SEVERE ASTHMA
#GSK #depemokimab #severeasthma #Exdensur #CRSwNP #respiratory #immunology #inflammation #Nucala #mepolizumab #COPD #rarediseases #SerumLifeScienceEurope #Anktiva #NMIBC #SFLPharma #Aumseqa #NSCLC #Cytokinetics #Myqorzo #hypertrophiccardiomyopathy #Moderna #Mnexspike #COVID19vaccine
zurl.co/l8WfN
zurl.co/l8WfN
GSK closes on approval of asthma hope depemokimab
GSK is poised for the first major approval of depemokimab, a long-acting drug for severe asthma that can be dosed just twice a year.
pharmaphorum.com
December 16, 2025 at 1:22 PM
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps
https://www.newsbeep.com/uk/318107/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
https://www.newsbeep.com/uk/318107/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps - United Kingdom News Beep
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first twice-yearly biological
www.newsbeep.com
December 16, 2025 at 12:42 AM
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps
https://www.newsbeep.com/uk/318107/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
https://www.newsbeep.com/uk/318107/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps
https://www.newsbeep.com/nz/185439/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
https://www.newsbeep.com/nz/185439/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps - New Zealand News Beep
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first twice-yearly biological
www.newsbeep.com
December 15, 2025 at 10:15 PM
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps
https://www.newsbeep.com/nz/185439/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
https://www.newsbeep.com/nz/185439/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps
https://www.newsbeep.com/us/350827/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
https://www.newsbeep.com/us/350827/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps - United States News Beep
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first twice-yearly biological
www.newsbeep.com
December 15, 2025 at 9:54 PM
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps
https://www.newsbeep.com/us/350827/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
https://www.newsbeep.com/us/350827/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps
https://www.europesays.com/uk/634699/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
https://www.europesays.com/uk/634699/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps - United Kingdom
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first twice-yearly biological
www.europesays.com
December 15, 2025 at 9:40 PM
UK approves the first twice yearly biological medicine for asthma and severe chronic rhinosinusitis with nasal polyps
https://www.europesays.com/uk/634699/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
https://www.europesays.com/uk/634699/
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (15 December 2025) approved depemokimab (Exdensur), the first…
GSK’s Exdensur Approved In UK To Treat Asthma, Rhinosinusitis
December 15, 2025 at 8:38 PM
GSK’s Exdensur Approved In UK To Treat Asthma, Rhinosinusitis
GSK’s Exdensur Approved In UK To Treat Asthma, Rhinosinusitis
December 15, 2025 at 8:37 PM
GSK’s Exdensur Approved In UK To Treat Asthma, Rhinosinusitis